Huons Global Consortium Signs Technology Transfer and Production Agreement for Sputnik V Vaccine

Sputnik V, the COVID-19 vaccine developed by Russia [Image source=Reuters Yonhap News]

[Asia Economy Reporter Chunhee Lee] Huons Global announced on the 16th that it has formed a consortium with Prestige BioPharma, Humedix, and Boran Pharma and signed a technology transfer agreement with the Russian Direct Investment Fund (RDIF) for the production of the Sputnik V COVID-19 vaccine.

The Huons Global consortium plans to start pilot vaccine production in August through the technology transfer. They intend to establish facilities capable of producing over 100 million doses per month by leveraging the capabilities of each company. Through this, they plan to flexibly respond to the quantities requested by RDIF.

The Sputnik V vaccine reported Phase 3 clinical trial results in the medical journal The Lancet in February, showing a preventive efficacy of 91.6%. It has been approved for use in over 60 countries worldwide, including Russia, Iran, Argentina, Algeria, and Hungary. The European Medicines Agency (EMA) also began its review earlier this month.

A Huons Global official stated, "Although the specific quantities cannot be disclosed due to confidentiality agreements, the four companies agreed to form a consortium to meet the quantities requested by RDIF," adding, "Since supply is possible to over 60 countries worldwide that have approved the use of Sputnik V, we will contribute to ending COVID-19."

This content was produced with the assistance of AI translation services.